[Current therapeutic agents: dornase alfa].
The authors present dornase alfa, a new drug for the long-term treatment of patients with cystic fibrosis: clinical interest, practical and economic aspects.
Baran
D
D
Service de Pneumologie Pédiatrique, Hôpital Erasme, Bruxelles.
Sternon
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D003850:Deoxyribonuclease I / Q000627:therapeutic use*; D005100:Expectorants / Q000627:therapeutic use*; D006801:Humans; D008176:Lung Volume Measurements; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D005100:Expectorants; D011994:Recombinant Proteins; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I